Health Check: Bug buster Genetic Signatures' US expansion is a jumbo-sized task
BTC Health makes a (literally) lifesaving sale
The lessons from Sarepta's billion-dollar FDA woes
Gut disease diagnostics provider Genetic Signatures (ASX:GSS) is finding its US market entry more elephantine than first envisaged and has made some changes 'to better align with current strategy and needs'.
On June 4 last year the US Food and Drug Administration (FDA) approved Genetic's Easyscreen, which can detect eight gastrointestinal (GI) parasites accounting for 90% of all tummy bugs.
On the same day the company launched a $30 million capital raise to support the US push and announced a new CEO (former Roche Diagnostics exec Allison Rossiter).
Genetic expected to be selling in the US within 60 to 90 days.
Today, Genetic says the US sales ramp-up has been 'impacted by prospective customers' internal processes, competing priorities, preference for enhanced workflow and uncertainty in the US healthcare environment.'
In part, the company discovered that clients craved more automated sample processing.
In response, Genetic has entered a three-way 'strategic partnership' with a mob called Tecan (lab automation) and Repado (compliant in vitro diagnostics).
This threesome will result in a 'scalable suite of fully automated diagnostic platforms for syndromic testing labs'.
Genetic doesn't mention any dollars, so we presume the financial impact is immaterial.
Speaking of finances, Genetic today reported June quarter sales of $4.4 million.
This was 52% higher than the March stanza, reflecting higher seasonal testing during the Australian flu season.
But turnover was flat on a year-on-year comp.
Having expended a net $5.95 million, Genetic ended the quarter with still-healthy cash of $30.9 million.
Microba GI testing sales are on tract
Still on tummy bugs, microbiome testing outfit Microba Life Sciences (ASX:MAP) has met its guidance with full-year revenue of $15.67 million, 30% higher year on year.
June (fourth) quarter revenue fell 13.5% to $4.2 million, the result of the company shedding a non-core research services business.
Microba has commercialised two clinical tests, to assess and manage GI patients.
The flagship Metaxplore tests assess a range of markers to appraise the GI tract and presents the results in a clear report.
Metapanel is the 'first line' test to determine whether the patient has a pathogen that can be treated simply with antibiotics.
Currently Metaxplore is sold in Australia and the UK, while Metapanel is available locally via the company's partner and biggest shareholder, Sonic Healthcare (ASX:SHL).
Microba chief Dr Luke Reid says Microba has a 'well considered plan' for US rollout, based on creating a beachhead in one city.
Mayne they could swap notes with Genetic's management.
Locally Microba sold 3451 Metaexplore tests during the quarter, up 88%. Microba also sold 266 Metapanel tests here (up 85%) and 429 in the UK (the test was only launched there in May).
Microba recorded net cash outflows of $5.56 million for the quarter, but management affirms the Australian and UK ops should be break-even this year.
BTC Health's PDF format suits investors
One of the more unusual life science plays on the bourse, medical product distributor BTC Health (ASX:BTC) has secured a $500,000 equipment order with Adelaide's Women's and Children's Hospital.
The order is for extracorporeal membrane oxygenation (ECMO) and follows a similar deal with Melbourne's Royal Children's Hospital.
ECMOs take over the work of the heart and lungs when these organs cannot perform their duties.
BTC Health is building a portfolio of diverse yet specialist medical devices, such as heart valves and infusion pumps.
BTC is a valuable pooled development fund (PDF), a remnant of a Keating-era initiative to bolster investment in small business.
PDFs pay only 15% tax on income and capital gains, but any returns to shareholders are tax free.
Only 17 PFDs remain and – like coastal property – God is not creating any more of them.
BTC chief Dr Richard Treagus previously headed generic drug play Acrux, the sector's only other PDF.
BTC posted December half revenue of $5.3 million, with underlying earnings of $200,000.
The company expects to have remained in the black for the full year to June 30 with a 'pathway to sustainable growth'.
Sarepta 'is worth nothing'
Could a $US1.31 billion company really be worth nothing?
US investment bank H.C. Wainwright thinks so, having ascribed a 'price target' of yada and zip to the Sarepta Therapeutics on the back of the Nasdaq-listed entity's drug strife.
Last week the FDA asked Sarepta to voluntarily halt shipments of its Elevidys gene therapy, for muscular dystrophy.
This follows the death of two patients from liver toxicity issues and the third from a separate experimental gene therapy treatment.
Defying the agency, Sarepta said it would continue to ship the therapy to ambulatory patients, but maintain a halt for wheelchair-bound ones.
The deaths pertained to the latter.
The FDA approved Elevidys two years ago for walking patients aged four or older, with the Duchenne muscular dystrophy (DMD) gene mutation.
A year later the agency expanded the assent to non-ambulatory patients.
Sarepta shares shed up to 40% on Friday and a further 5% overnight.
Don't fight City Hall
H.C. Wainwright previously had a US$10 valuation on Sarepta, compared with the stock's overnight close of US$13.32.
The firm describes Sarepta's fight with the FDA as 'unwinnable' and – indeed – you can't beat City Hall.
Elevidys generated US$384 million of net revenue in the December quarter, more than half of Sarepta's total revenue of US$638 million.
The lesson for everyone is that even when drug makers have done the hard yards of developing and commercialising a therapy, success is still not guaranteed.
In one of the best-known cases, in 1999 the FDA approved Merck's Vioxx, for osteoarthritis pain. After racking up billions in sales Merck withdrew the drug from sale in 2004, amid concerns it could cause heart attacks and strokes.
Locally, Percheron Therapeutics (ASX:PER) is reinventing itself after its DMD therapy failed in phase IIb stage last December.
Perhaps the company dodged a bullet by discovering the problems early in the piece, but wounded investors might disagree.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Perth Now
an hour ago
- Perth Now
Wall Street inches up amid Trump EU trade remarks
The S&P 500 and the Dow edged up in tepid trading as investors assessed President Donald Trump's latest comments on trade discussions with the European Union and his hints that a rate cut from the US Federal Reserve was imminent. Trump said the odds of a US-EU trade deal were "50-50" and suggested after a meeting with Fed Chair Jerome Powell that a rate cut might be on the horizon. A spate of upbeat second-quarter earnings also supported Wall Street's record run. In early trading on Friday, the Dow Jones Industrial Average rose 70.76 points, or 0.16 per cent, to 44,764.67 - creeping up towards its December 4 record high. The S&P 500 added 10.70 points, or 0.17 per cent, to 6,374.05, and the Nasdaq Composite gained 1.87 points, or 0.01 per cent, to 21,059.83. Expectations were rife that the European bloc would soon sign an agreement with Washington. Meanwhile, US negotiations with South Korea gathered momentum ahead of the August 1 deadline set for most countries as they scrambled to avoid Trump's steep import levies. A wave of trade agreements including pacts with Japan, Indonesia and the Philippines set all three major indexes on track for a strong weekly finish, if the gains hold. Tariffs have had only a small impact on inflation and the economy has not shown many negative effects from shifts in trade policy, according to Paul Ashworth, chief North America economist at Capital Economics. Because of this, he said, even a slight increase in inflation would likely be enough to keep the Fed from cutting rates again. Of the 168 companies in the S&P 500 that have reported earnings as of Friday, 79.8 per cent beat analyst expectations, according to data compiled by LSEG. However, there were a few setbacks during the week. Heavyweights Tesla and General Motors stumbled and were on track for their steepest weekly declines in nearly two months if losses hold. Tesla CEO Elon Musk warned of tougher quarters ahead amid shrinking US EV subsidies, while General Motors took a hit after absorbing a $US1.1-billion ($A1.7 billion) blow in its second-quarter earnings from Trump's tariffs. Intel dropped 9.0 per cent after the chipmaker forecast steeper third-quarter losses than the Street expected and announced plans to slash jobs. All eyes will be on the US Federal Reserve's monetary policy meeting next week, with bets indicating that policymakers are likely to keep interest rates unchanged as they evaluate the impact of tariffs on inflation. The central bank is under immense scrutiny from the White House, with President Trump leading a censure campaign against Chair Jerome Powell for not reducing borrowing costs, while often hinting that he would sack the top policymaker. In a surprise move, Trump escalated the pressure by making a rare visit to the Fed headquarters on Thursday, where he criticised its $US2.5-billion ($A3.8 billion) renovation project. According to CME's FedWatch tool, traders now see a nearly 61.8 per cent chance of a rate cut as soon as September. Among other stocks, Newmont added 7.4 per cent after the gold miner surpassed Wall Street expectations for second-quarter profit. Health insurer Centene posted a surprise quarterly loss, but its shares gained 3.0 per cent. Paramount Global rose 2.1 per cent after US regulators approved its $US8.4 billion ($A12.8 billion) merger with Skydance Media.
West Australian
8 hours ago
- West Australian
ASX falls for third straight session on banks and miners
A slump in the price of iron ore and Australians dumping their bank stocks saw the local market slide for the third straight trading day. The benchmark ASX200 dropped 42.5 points or 0.49 per cent to 8,666.9 points on Friday while the broader All Ordinaries lost 45.10 points or 0.50 per cent to close the week at 8,934.30. Australia's dollar also fell and at the time of writing was buying 65.76 US cents. The falls were broad based with seven of the 11 sectors ending the day in the red, led by the materials, financials and healthcare sector. BHP shares fell 1.92 per cent to $40.80, Fortescue shares dropped 3.42 per cent of $18.35 and Rio Tinto traded down 0.83 per cent to $118.86 on the back of a falling iron ore price. Singapore iron ore futures slumped 1.7 per cent to $103.35. The drop follows investors fear of an oversupply of the commodity. The big four banks continued their sell-off with CBA down 0.35 per cent to $172.87, NAB down 0.40 per cent to $37.51, Westpac slumping 0.78 per cent to $33.03 and ANZ down 0.72 per cent to $30.22. Market heavyweight CSL also fell 0.61 per cent to $267.92, while Sigma Healthcare lost 0.70 per cent to $2.84 and Cochlear slid 0.38 per cent to $312.83. AMP chief economist and head of investment strategy Shane Oliver said the Australian market fell during the week even though Wall Street continued to reset record highs. 'Resources and health stocks rose but this was more than offset by falls in consumer and financial shares, with CBA coming under after it nearly doubled in price over two years,' he said. Dr Oliver said the Australian sharemarket was still on track for a solid July up 1.4 per cent so far although the gains could be short lived. 'With lots of good news already factored in and valuations stretched, markets are a bit vulnerable to a correction over the seasonally weaker months of August and September with a long worry list,' he said. Shares in anti-drone technology business DroneShield slumped 10.09 per cent to $3.03. This was on the back of no announcement and could be investors taking profit after the shares surged more than 300 per cent so far this year. Bapcor shares gained 1.64 per cent to $3.72 following after tanking nearly 30 per cent to a five-year low on Thursday on the back of its latest earnings forecast. The Autobarn and Midas owner said statutory net profits after tax would lie between $31m-$34m. Specialist alternative investment manager Regal Partners surged 9.02 per cent to $2.90 after announcing a 7 per cent increase in funds under management to $17.7bn. Shares in Newmont also shined, gaining 3.81 per cent to $95.38 after the US gold miner announced a 9 per cent rise in net income for the second quarter and a $4.6bn share buyback program.
Perth Now
8 hours ago
- Perth Now
ASX drops on banks and miners
A slump in the price of iron ore and Australians dumping their bank stocks saw the local market slide for the third straight trading day. The benchmark ASX200 dropped 42.5 points or 0.49 per cent to 8,666.9 points on Friday while the broader All Ordinaries lost 45.10 points or 0.50 per cent to close the week at 8,934.30. Australia's dollar also fell and at the time of writing was buying 65.76 US cents. The ASX 200 fell for the third straight day of trading. NewsWire / Christian Gilles Credit: News Corp Australia The falls were broad based with seven of the 11 sectors ending the day in the red, led by the materials, financials and healthcare sector. BHP shares fell 1.92 per cent to $40.80, Fortescue shares dropped 3.42 per cent of $18.35 and Rio Tinto traded down 0.83 per cent to $118.86 on the back of a falling iron ore price. Singapore iron ore futures slumped 1.7 per cent to $103.35. The drop follows investors fear of an oversupply of the commodity. The big four banks continued their sell-off with CBA down 0.35 per cent to $172.87, NAB down 0.40 per cent to $37.51, Westpac slumping 0.78 per cent to $33.03 and ANZ down 0.72 per cent to $30.22. Market heavyweight CSL also fell 0.61 per cent to $267.92, while Sigma Healthcare lost 0.70 per cent to $2.84 and Cochlear slid 0.38 per cent to $312.83. AMP chief economist and head of investment strategy Shane Oliver said the Australian market fell during the week even though Wall Street continued to reset record highs. 'Resources and health stocks rose but this was more than offset by falls in consumer and financial shares, with CBA coming under after it nearly doubled in price over two years,' he said. Dr Oliver said the Australian sharemarket was still on track for a solid July up 1.4 per cent so far although the gains could be short lived. 'With lots of good news already factored in and valuations stretched, markets are a bit vulnerable to a correction over the seasonally weaker months of August and September with a long worry list,' he said. Seven of the 11 sectors finished in the red. NewsWire / Max Mason-Hubers Credit: News Corp Australia Shares in anti-drone technology business DroneShield slumped 10.09 per cent to $3.03. This was on the back of no announcement and could be investors taking profit after the shares surged more than 300 per cent so far this year. Bapcor shares gained 1.64 per cent to $3.72 following after tanking nearly 30 per cent to a five-year low on Thursday on the back of its latest earnings forecast. The Autobarn and Midas owner said statutory net profits after tax would lie between $31m-$34m. Specialist alternative investment manager Regal Partners surged 9.02 per cent to $2.90 after announcing a 7 per cent increase in funds under management to $17.7bn. Shares in Newmont also shined, gaining 3.81 per cent to $95.38 after the US gold miner announced a 9 per cent rise in net income for the second quarter and a $4.6bn share buyback program.
